Transplantation in Hematology and Oncology II

With contributions by

Contents

Cellular Therapy: Targets and Effectors
Adoptive Immunotherapy in Chimeras

The Roles of the Chemokine SDF-1 and its Receptor CXCR4 in Human Stem Cell Migration and Repopulation of NOD/SCID and B2mnull NOD/SCID mice
T. Lapidot ................................................................. 11

Towards Adoptive Immunotherapy Using High Affinity T Cell Receptors
M. Theobald ................................................................. 25

New Antigens and Avenues to Immunotherapy of Cancer
J. L. Schultze ................................................................. 29

Allogeneic Cell Therapy with Antigen-Specific Cytotoxic T Lymphocytes (CTL) for Malignant Melanoma
A. Nolte, J. Slotty, C. Beike, W. E. Berdel, and J. Kienast ........................................... 37

New Conditioning Strategies in Allogeneic Stem Cell Transplantation
Intensification of the Conditioning Regimen for Patients with high-risk AML and MDS: 3 year Experience of using an 188Re – Labelled anti – CD 66 Monoclonal Antibody
Dose Reduced Conditioning for Allogeneic Blood Stem Cell Transplantation from Sibling and Unrelated Donors in 51 Patients
M. Bornhäuser, C. Thiede, F. Kroschinsky, A. Neubauer, and G. Ehninger ............................... 59

Pharmacokinetics of Conditioning Regimens
G. Würthwein, and J. Boos ................................. 74

Megadose Stem Cell Transplantation
M. F. Martelli ............................................. 79

HD-Ara-C in the Conditioning Regimen for BMT in Acute Leukemias

TBI-Based Reduced Intensity Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) in Patients with High-Risk Hematologic Malignancies
M. J. Kröger, A. Schuck, M. Kiehl, G. Silling, R. Leo, C. Scheffold, W. E. Berdel, and J. Kienast ................. 91

Total Marrow Irradiation (TMI), Busulfan, and Cyclophosphamide for Allografting in Multiple Myeloma. A Pilot Study

Stem Cell Mobilisation, Processing and Characteristics

Factors Influencing PBPC Mobilisation and Collection in Haematological Malignancies
Successful Purging of Stem Cell Products Using CD34 Selection

Autologous Transplantation of Non-Cryopreserved HSCs in Oncologic Patients with Poor Prognosis:
First Experience in the Ukraine
O. Ryzhak, S. Donska, J. Bazaluk, and N. Genkina ....... 130

A Randomized Comparison of Once Versus Twice Daily rhG-CSF (Filgrastim) for Stem Cell Mobilisation in Healthy Donors for Allogeneic Transplantation

CD 133/CD34 Expression on Hematopoietic Stem-/Progenitor Cells and Acute Leukemic Blasts

Identification of Minimal Residual Leukemia
Applying Continuous Gating
S. Wehner, H.-D. Kleine, B. Kornhuber, and U. Ebener . 156

Cord Blood Transplantation
Pilot Study – Lymphocyte Subset Reconstitution after Cord Blood Transplantation

Altered Growth Characteristics of Cord Blood after in vivo Exposure of the Mother to Chemotherapy

Mismatched Donor Transplantation
Bone Marrow Transplantation from Mismatched Unrelated Donors
Immune Reconstitution after Haploidentical Stem Cell Transplantation

Clinical Transplantation – Hematologic Malignancies

Autografting and Allografting for Chronic Lymphocytic Leukemia: Is there a Rationale?
P. Dreger ................................................................. 197

Results of Stem Cell Transplantation in Children with CML in Comparison with Treatment with Cytostatics alone or with Interferon alfa. Report of the Polish Children’s Leukemia/Lymphoma Study Group

Comparison of Allogeneic Matched Related Stem Cell Transplantation in 1st CR with Chemotherapy alone in Children with High-Risk AML
D. Reinhardt, M. Zimmermann, J. Ritter, Ch. Bender-Götze, and U. Creutzig ................. 210

Stem Cell Transplantation in Acute Myeloid Leukemia after Conditioning with Busulfan, Cyclophosphamide and Different Dosages of Etoposide (VP-16)
The Occurrence of Acute Graft-Versus-Host Disease and Infectious Complications in Patients with Acute and Chronic Myeloid Leukemia who Underwent Allogeneic Peripheral Blood Stem Cell Transplantation
M. Machaczka, M. Rucinska, J. Wilczynski, B. Zawilinska, B. Platkowska-Jakubas, D. Uracz, and A. B. Skotnicki . . 228

Long-Term Survival after Stem Cell Transplant in Adult Acute Lymphoblastic Leukemia
X. Thomas, C. Danaila, N. Raus, J. Troncy, C. Sebban, V. Lheritier, M. Michallet, and D. Fiere ................. 233

Clinical Transplantation – Solid Tumors

Autologous Transplantation in Breast Cancer in Europe and EBMT Data
G. Rosti, P. Ferrante, A. Cariello, G. Papiani, U. De Giorgi, P. Giovanis, C. Dazzi, and M. Marangolo . . 245

First-Line and Salvage High-Dose Chemotherapy in Patients with Germ-Cell Tumors
O. Rick, W. Siegert, and J. Beyer ....................... 253

High Dose Chemotherapy in High-Risk Ewing Tumours: Results in 156 (EI)CESS Patients

Rapid Sequence Tandem Transplant in Children with High-Risk Neuroblastoma

Anti-Angiogenesis

Angiogenesis Inhibitor TNP-470 During Bone Marrow Transplant and in Minimal Residual Disease
Challenges in the Treatment of Fungal Infections

Prophylaxis of Fungal Infections in Neutropenic Patients with Hematologic Malignancies

F. Kroschinsky, and U. Schuler .......................... 301

Subject Index .......................... 309
Preface

Hematopoietic stem cell and immune cell transplantation has continued as a promising therapeutic alternative and a fascinating area of cell biology as well as a field of persistent procedural problems. This explains why substantial parts of basic research on cell growth and differentiation, immune tolerance and antitumor effects, gene transfer, minimal residual disease and supportive care have settled around clinical transplantation in hematology and oncology. This second volume again updates the current role of allogeneic and autologous transplantation in leukemias, lymphomas and solid cancers, including controversial strategies and novel experimental approaches.

In particular, cellular immune therapy, new conditioning strategies, mismatched donor transplantation, updated clinical transplantation, antiangiogenesis and strategies against fungal infections are focused upon. Outstanding representatives of leading groups guarantee first-hand information and indicate how we can work and cooperate more effectively to the benefit of our patients.

The editors are indebted to the Gesellschaft zur Bekämpfung der Krebskrankheiten Nordrhein-Westfalen for a substantial support of the publication. They also acknowledge the major contribution of Beate Kosel as coordinator of the editorial work.

Wolfgang E. Berdel
Heribert Jürgens
Thomas Büchner
Jörg Ritter
Joachim Kienast
Josef Vormoor
Transplantation in Hematology and Oncology II
Berdel, W.E.; Jürgens, H.; Büchner, Th.; Ritter, J.;
Kienast, J.; Vormoor, J. (Eds.)
2003, XII, 312 p., Hardcover
ISBN: 978-3-540-42155-9